SynBioBeta Speaker
Simon Kohl
Latent Labs
Founder & CEO
Dr. Simon Kohl is the founder and CEO of Latent Labs, a frontier AI lab that enables biotech and pharmaceutical companies to generate and optimize proteins. Simon previously started and co-led DeepMind's protein design team and was a senior research scientist on the Nobel Prize-winning AlphaFold2 project, where he developed the crucial pLDDT confidence quantification system now widely used to predict laboratory success in protein design. At Latent Labs, backed by $50M in total funding from investors including Radical Ventures, Sofinnova Partners, Google Chief Scientist Jeff Dean and CEO of Anthropic Dario Amodei, Simon leads a team innovating frontier models that use cutting-edge generative techniques to computationally create new therapeutic molecules like antibodies and enzymes. The company is focused on enabling partners at scale to tackle challenging targets, develop precision medicines, and accelerate development timelines through their AI protein design platform.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Simon
This Year
•
-
AIxBIO
Keynote Brought to you by Latent Labs
Get a Ticket
Featuring
Simon Kohl
Latent Labs
Founder & CEO
•
-
AIxBIO
Keynote Brought to you by Latent Labs
Get a Ticket
Featuring
Simon Kohl
Latent Labs
Founder & CEO
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Get a Ticket
Featuring
Georgia Lu
Magnet Ventures
Founder & Mng Partner
AI-biotech investor blending M&A instincts with founder coaching.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Simon Kohl
Latent Labs
Founder & CEO
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Get a Ticket
Featuring
Georgia Lu
Magnet Ventures
Founder & Mng Partner
AI-biotech investor blending M&A instincts with founder coaching.
Jason Gammack
Ansa Biotechnologies
CEO
Turning DNA synthesis into a predictable, on-time “reagent.”
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Simon Kohl
Latent Labs
Founder & CEO
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
